S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.17 (-0.15%)
AAPL   171.28 (-1.17%)
MSFT   420.06 (-0.33%)
META   486.26 (-1.54%)
GOOGL   150.72 (-0.10%)
AMZN   180.14 (+0.17%)
TSLA   177.42 (-1.34%)
NVDA   905.75 (+0.36%)
NIO   4.57 (-2.14%)
AMD   180.85 (+0.70%)
BABA   72.42 (+1.16%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.15 (-2.76%)
DIS   122.66 (+1.39%)
AMC   3.69 (-14.98%)
PFE   27.98 (+0.72%)
PYPL   67.18 (+0.92%)
XOM   115.84 (+0.76%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.17 (-0.15%)
AAPL   171.28 (-1.17%)
MSFT   420.06 (-0.33%)
META   486.26 (-1.54%)
GOOGL   150.72 (-0.10%)
AMZN   180.14 (+0.17%)
TSLA   177.42 (-1.34%)
NVDA   905.75 (+0.36%)
NIO   4.57 (-2.14%)
AMD   180.85 (+0.70%)
BABA   72.42 (+1.16%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.15 (-2.76%)
DIS   122.66 (+1.39%)
AMC   3.69 (-14.98%)
PFE   27.98 (+0.72%)
PYPL   67.18 (+0.92%)
XOM   115.84 (+0.76%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.17 (-0.15%)
AAPL   171.28 (-1.17%)
MSFT   420.06 (-0.33%)
META   486.26 (-1.54%)
GOOGL   150.72 (-0.10%)
AMZN   180.14 (+0.17%)
TSLA   177.42 (-1.34%)
NVDA   905.75 (+0.36%)
NIO   4.57 (-2.14%)
AMD   180.85 (+0.70%)
BABA   72.42 (+1.16%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.15 (-2.76%)
DIS   122.66 (+1.39%)
AMC   3.69 (-14.98%)
PFE   27.98 (+0.72%)
PYPL   67.18 (+0.92%)
XOM   115.84 (+0.76%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.17 (-0.15%)
AAPL   171.28 (-1.17%)
MSFT   420.06 (-0.33%)
META   486.26 (-1.54%)
GOOGL   150.72 (-0.10%)
AMZN   180.14 (+0.17%)
TSLA   177.42 (-1.34%)
NVDA   905.75 (+0.36%)
NIO   4.57 (-2.14%)
AMD   180.85 (+0.70%)
BABA   72.42 (+1.16%)
T   17.63 (+0.46%)
F   13.18 (+0.92%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.15 (-2.76%)
DIS   122.66 (+1.39%)
AMC   3.69 (-14.98%)
PFE   27.98 (+0.72%)
PYPL   67.18 (+0.92%)
XOM   115.84 (+0.76%)

Harmony Biosciences (HRMY) Stock Price, News & Analysis

$33.81
+0.29 (+0.87%)
(As of 01:03 PM ET)
Today's Range
$32.62
$33.98
50-Day Range
$29.93
$35.06
52-Week Range
$18.61
$39.26
Volume
71,552 shs
Average Volume
364,727 shs
Market Capitalization
$1.92 billion
P/E Ratio
15.95
Dividend Yield
N/A
Price Target
$41.00

Harmony Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
23.3% Upside
$41.00 Price Target
Short Interest
Bearish
19.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.52mentions of Harmony Biosciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$389,536 Sold Last Quarter
Proj. Earnings Growth
31.33%
From $3.00 to $3.94 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.46 out of 5 stars

Medical Sector

141st out of 939 stocks

Pharmaceutical Preparations Industry

53rd out of 433 stocks

HRMY stock logo

About Harmony Biosciences Stock (NASDAQ:HRMY)

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

HRMY Stock Price History

HRMY Stock News Headlines

Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
HRMY Oct 2024 35.000 put
HRMY Apr 2024 30.000 put
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
HRMY Jul 2024 30.000 put
Harmony Biosciences Receives FDA Priority Review For Wakix
HRMY Mar 2024 30.000 call
See More Headlines
Receive HRMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/28/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:HRMY
Fax
N/A
Employees
246
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$41.00
High Stock Price Target
$59.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+22.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$128.85 million
Pretax Margin
29.79%

Debt

Sales & Book Value

Annual Sales
$582.02 million
Cash Flow
$2.73 per share
Book Value
$7.97 per share

Miscellaneous

Free Float
40,647,000
Market Cap
$1.90 billion
Optionable
Optionable
Beta
0.72
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Jeffrey S. Aronin (Age 56)
    Founder & Non-Executive Chairman
    Comp: $19.6k
  • Dr. Jeffrey M. Dayno M.D. (Age 67)
    President, CEO & Director
    Comp: $762.15k
  • Mr. Jeffrey Dierks M.B.A.Mr. Jeffrey Dierks M.B.A. (Age 52)
    Executive VP & Chief Commercial Officer
    Comp: $662.1k
  • Mr. Andrew Serafin J.D. (Age 49)
    M.B.A., Executive VP & Chief Strategy Officer
    Comp: $605.42k
  • Mr. David Bradshaw
    Head of Technical Operations
  • Luis Sanay
    Head of Investor Relations
  • Mr. Christian Ulrich
    General Counsel & Corporate Secretary
  • Ms. Tricia Glover
    Chief Compliance Officer
  • Ms. Audrey Murphy SPHR
    Head of Human Resources
  • Ms. Cate McCanless
    Head of Corporate Affairs & Public Policy

HRMY Stock Analysis - Frequently Asked Questions

Should I buy or sell Harmony Biosciences stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harmony Biosciences in the last year. There are currently 2 sell ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HRMY shares.
View HRMY analyst ratings
or view top-rated stocks.

What is Harmony Biosciences' stock price target for 2024?

8 equities research analysts have issued 12 month price objectives for Harmony Biosciences' stock. Their HRMY share price targets range from $27.00 to $59.00. On average, they expect the company's share price to reach $41.00 in the next twelve months. This suggests a possible upside of 23.3% from the stock's current price.
View analysts price targets for HRMY
or view top-rated stocks among Wall Street analysts.

How have HRMY shares performed in 2024?

Harmony Biosciences' stock was trading at $32.30 at the start of the year. Since then, HRMY shares have increased by 3.0% and is now trading at $33.26.
View the best growth stocks for 2024 here
.

When is Harmony Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our HRMY earnings forecast
.

How were Harmony Biosciences' earnings last quarter?

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) issued its quarterly earnings data on Thursday, February, 22nd. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.74 by $0.29. The company had revenue of $168.40 million for the quarter, compared to the consensus estimate of $168.90 million. Harmony Biosciences had a net margin of 22.16% and a trailing twelve-month return on equity of 27.49%. The business's quarterly revenue was up 31.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.01 EPS.

What guidance has Harmony Biosciences issued on next quarter's earnings?

Harmony Biosciences updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $700.0 million-$720.0 million, compared to the consensus revenue estimate of $712.3 million.

What other stocks do shareholders of Harmony Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), Boeing (BA), Berry Global Group (BERY), Bunge Global (BG), Carrier Global (CARR), Commercial Metals (CMC), Canadian Solar (CSIQ), Deere & Company (DE) and Eastman Chemical (EMN).

When did Harmony Biosciences IPO?

Harmony Biosciences (HRMY) raised $101 million in an IPO on Wednesday, August 19th 2020. The company issued 4,700,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler served as the underwriters for the IPO.

Who are Harmony Biosciences' major shareholders?

Harmony Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.27%), Vanguard Group Inc. (6.47%), Pacer Advisors Inc. (2.09%), Dimensional Fund Advisors LP (1.26%), abrdn plc (0.91%) and Federated Hermes Inc. (0.90%). Insiders that own company stock include Andreas Wicki, Jack Nielsen, Jeffrey Dierks, Jeffrey M Dayno, Jeffrey M Dayno, John C Jacobs and John C Jacobs.
View institutional ownership trends
.

How do I buy shares of Harmony Biosciences?

Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HRMY) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners